Esophageal Cancer: Types, Surgery & Neoadjuvant Treatment

Esophageal cancer is the seventh most common cancer worldwide and the sixth leading cause of cancer death globally. Approximately 22,000 new cases are diagnosed annually in the United States. It is a particularly challenging malignancy because of its anatomic location, tendency for early lymphatic spread, and frequent late-stage diagnosis. The overall five-year survival rate is approximately 21%, though outcomes have been steadily improving with advances in multimodal therapy.

The epidemiology of esophageal cancer has shifted dramatically in Western countries over the past four decades. Adenocarcinoma of the distal esophagus and gastroesophageal junction (GEJ) has risen by approximately 600% since the 1970s and now accounts for more than 60% of esophageal cancers in the United States, overtaking squamous cell carcinoma as the predominant subtype.

Types of Esophageal Cancer

Esophageal Adenocarcinoma

Adenocarcinoma typically develops in the lower third of the esophagus and the gastroesophageal junction (GEJ). It arises from the columnar epithelium of Barrett's esophagus, following the progression from normal squamous epithelium to intestinal metaplasia (Barrett's) to low-grade dysplasia to high-grade dysplasia to invasive cancer. Key risk factors include:

• Chronic GERD — Longstanding acid reflux is the primary driver. Patients with frequent reflux symptoms (>3 times per week) have a 7-fold increased risk compared to asymptomatic individuals.
• Barrett's esophagus — Present in approximately 10–15% of patients with chronic GERD. The annual progression rate from Barrett's without dysplasia to adenocarcinoma is approximately 0.5%.
• Obesity — Central adiposity increases risk through mechanical effects (increased intra-abdominal pressure worsening reflux) and metabolic effects (elevated leptin, insulin resistance, chronic inflammation).
• Male sex — Esophageal adenocarcinoma has a striking 8:1 male-to-female ratio.
• Smoking — Approximately 2-fold increased risk. Unlike squamous cell carcinoma, the risk does not fully normalize after smoking cessation.

Esophageal Squamous Cell Carcinoma (ESCC)

Squamous cell carcinoma arises from the squamous epithelium that normally lines the esophagus and can develop anywhere along its length, though it is most common in the middle and upper thirds. It remains the predominant subtype globally, particularly in the "Asian esophageal cancer belt" (Iran through Central Asia to China). Key risk factors include:

• Tobacco use — The strongest risk factor in Western populations. Risk increases with intensity and duration of use.
• Alcohol consumption — A major independent risk factor with a synergistic effect when combined with smoking (the combined risk is multiplicative, not merely additive).
• Hot beverages — Consumption of very hot (>65°C) drinks, classified as "probably carcinogenic" by the IARC.
• Nutritional deficiencies — Low intake of fruits, vegetables, and vitamins A, C, and E.
• Achalasia — A motility disorder that increases ESCC risk, with a cumulative incidence of approximately 3% over 25 years.
• Previous head and neck cancer — Shared risk factors (smoking, alcohol) and field cancerization.
• Tylosis — A rare inherited condition (RHBDF2 gene mutation) with near 100% lifetime risk of ESCC.

Barrett's Esophagus: Detection and Management

Barrett's esophagus (BE) is the replacement of the normal squamous epithelium of the distal esophagus with columnar epithelium containing goblet cells (intestinal metaplasia). It is the only known precursor to esophageal adenocarcinoma, and its management represents one of the most important cancer prevention strategies in gastroenterology.

Screening

Current guidelines (ACG, AGA) recommend screening endoscopy for Barrett's in patients with chronic GERD (>5 years) who have additional risk factors: age ≥50, male sex, Caucasian race, obesity, family history of Barrett's or esophageal adenocarcinoma, or smoking history.

Surveillance and Treatment of Dysplasia

Radiofrequency ablation (RFA) of Barrett's esophagus with dysplasia has been shown to eliminate the risk of progression to cancer in the majority of patients, with complete eradication of intestinal metaplasia achieved in 77–92% of cases.

Staging

Accurate staging is critical for treatment planning. The workup typically includes:

• Upper endoscopy with biopsy — For tissue diagnosis and assessment of tumor location and extent.
• Endoscopic ultrasound (EUS) — The most accurate modality for assessing the depth of tumor invasion (T stage) and regional lymph node involvement.
• PET-CT — Essential for detecting distant metastases and involved lymph nodes. Changes management in approximately 15–20% of patients.
• CT scan of chest and abdomen — Standard staging imaging.
• Staging laparoscopy — Recommended for GEJ tumors to rule out peritoneal disease not visible on imaging.

Surgical Treatment: Esophagectomy

Esophagectomy (surgical removal of the esophagus) remains the backbone of curative treatment for localized esophageal cancer. It is one of the most complex operations in surgical oncology, and outcomes are strongly influenced by hospital and surgeon volume.

Surgical Approaches

• Ivor Lewis esophagectomy — Involves a laparotomy (or laparoscopy) for gastric mobilization and creation of a gastric conduit, followed by a right thoracotomy (or thoracoscopy) for esophageal resection and intrathoracic anastomosis. The most common approach for mid- to distal esophageal and GEJ tumors.
• McKeown (three-incision) esophagectomy — Adds a cervical incision for a neck anastomosis. May be preferred for proximal esophageal tumors and allows for a more extensive esophageal resection. Higher risk of anastomotic leak but lower risk of mediastinitis if a leak occurs.
• Transhiatal esophagectomy — Performed through abdominal and cervical incisions without thoracotomy. Avoids the morbidity of chest opening but provides limited mediastinal lymph node dissection.
• Minimally invasive esophagectomy (MIE) — Performed laparoscopically and/or thoracoscopically, with or without robotic assistance. The TIME trial and subsequent studies have demonstrated reduced pulmonary complications, shorter hospital stays, and equivalent oncologic outcomes compared to open surgery. Increasingly adopted as the standard approach at high-volume centers.

Neoadjuvant Chemoradiation: The CROSS Protocol

The CROSS trial (Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study) established the global standard for neoadjuvant treatment of locally advanced esophageal cancer. This landmark Dutch randomized trial compared neoadjuvant chemoradiation followed by surgery to surgery alone.

The CROSS Regimen

• Chemotherapy: Carboplatin (AUC 2) and paclitaxel (50 mg/m²) administered weekly for 5 weeks
• Radiation: 41.4 Gy in 23 fractions, delivered concurrently with chemotherapy
• Followed by: Esophagectomy, typically 4–8 weeks after completion of chemoradiation

Key results from the CROSS trial:

• Median overall survival improved from 24.0 months (surgery alone) to 48.6 months (neoadjuvant chemoradiation plus surgery)
• Complete pathologic response (pCR) achieved in 29% of patients overall (49% for squamous cell carcinoma, 23% for adenocarcinoma)
• R0 (complete) resection rate improved from 69% to 92%
• No increase in surgical complications or perioperative mortality
• 5-year overall survival: 47% versus 33%

Adjuvant Immunotherapy After CROSS

The CheckMate 577 trial demonstrated that adjuvant nivolumab (given for 1 year after neoadjuvant chemoradiation and surgery) doubled disease-free survival in patients who did not achieve a complete pathologic response (22.4 months vs 11.0 months). This has established adjuvant nivolumab as the standard of care for patients with residual disease in the surgical specimen after CROSS-based neoadjuvant therapy.

Perioperative Chemotherapy

For GEJ adenocarcinomas, perioperative chemotherapy (without radiation) is an alternative to neoadjuvant chemoradiation. The FLOT regimen (fluorouracil, leucovorin, oxaliplatin, docetaxel), established by the FLOT4-AIO trial for gastric cancer, is also used for GEJ tumors, particularly Siewert type II and III tumors that are managed more like gastric cancer.

Definitive Chemoradiation (Non-Surgical)

For patients who are medically unfit for surgery, have unresectable disease, or have cervical esophageal cancer (where surgery would require laryngectomy), definitive chemoradiation is the primary treatment. The standard regimen is cisplatin plus 5-FU with concurrent radiation (50–50.4 Gy). While long-term cure is possible (approximately 20–30% of patients), locoregional recurrence rates are higher than with surgery-based approaches.

Systemic Therapy for Advanced Disease

First-Line Treatment

• Nivolumab plus chemotherapy — The CheckMate 648 trial established nivolumab plus cisplatin/5-FU (or nivolumab plus ipilimumab) as first-line options for advanced ESCC, with improved OS in PD-L1 positive patients.
• Pembrolizumab plus chemotherapy — The KEYNOTE-590 trial demonstrated improved OS with pembrolizumab plus cisplatin/5-FU compared to chemotherapy alone for both ESCC and adenocarcinoma, particularly in PD-L1 CPS ≥10 patients.
• Trastuzumab — For HER2-positive GEJ adenocarcinomas, added to platinum/fluoropyrimidine chemotherapy (as in gastric cancer).

Second-Line and Beyond

• Ramucirumab plus paclitaxel — Standard second-line treatment for adenocarcinoma (RAINBOW trial).
• Trastuzumab deruxtecan (Enhertu) — For HER2-positive GEJ adenocarcinomas after prior trastuzumab.
• Nivolumab or pembrolizumab monotherapy — For patients not previously treated with immunotherapy.

Palliative Treatment

For patients with incurable esophageal cancer, maintaining swallowing function and nutritional intake is a primary goal of palliative care:

• Esophageal stenting — Self-expanding metal stents (SEMS) provide rapid relief of dysphagia (difficulty swallowing) from obstructing tumors. Stents can be placed endoscopically as an outpatient procedure and provide immediate improvement in swallowing. Covered stents are preferred to reduce tumor ingrowth.
• Palliative radiation — External beam radiation or brachytherapy (intraluminal radiation) can relieve dysphagia and control bleeding. Brachytherapy provides more durable dysphagia relief than stenting alone, based on randomized evidence.
• Laser therapy and argon plasma coagulation — Endoscopic techniques to recanalize the esophageal lumen by destroying obstructing tumor tissue.
• Feeding tube placement — Percutaneous endoscopic gastrostomy (PEG) or jejunostomy tube for patients unable to maintain adequate oral intake.
• Nutritional support — Dietary counseling, oral nutritional supplements, and management of treatment-related swallowing difficulties.

Related Resources

• Cancer Treatment Overview
• Stomach Cancer Guide
• Lung Cancer Guide
• Understanding Chemotherapy
• Radiation Therapy Guide
• Cancer Screening Recommendations
• Find a Thoracic Surgeon or GI Oncologist